The Effect of Humalog and Lantus Insulin Injectables on Glycogen Phosphorylase B

Voiceover

Presenter(s)

Rylee Crowell

Abstract or Description

Using spectroscopy and enzyme kinetics techniques, the effects of injections of both Humalog, a short-term acting insulin, and Lantus, a long-acting insulin, were analyzed on the activity of glycogen phosphorylase B (GPB). The results showed that there were differences in the reactions to Lantus and Humalog. Lantus inhibited GPB activity for a longer period of time, which was consistent with its long-acting profile, whereas Humalog suppressed GPB activity quickly but temporarily. These findings shed light on the pharmacodynamic characteristics of these insulin injections and how glycemic control may be affected by them. Furthermore, because glucagon activates GPB, the opposite function of insulin, this study adds to the understanding of the compromises between insulin and glucagon. To maximize treatment outcomes, this research highlights the need for additional investigation into the metabolic effects of insulin analogs and provides guidance for individualized diabetes management strategies.

Mentor

Roberto De Guzman